Q2 Earnings Forecast for FTH Issued By HC Wainwright

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) – Equities research analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of Sensei Biotherapeutics in a note issued to investors on Monday, June 22nd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of ($0.63) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($16.61) EPS and FY2027 earnings at ($3.72) EPS.

Several other research analysts also recently commented on FTH. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $60.00.

Sensei Biotherapeutics Trading Up 3.5%

NASDAQ FTH opened at $24.00 on Wednesday. The company has a market cap of $32.21 million, a P/E ratio of -0.17 and a beta of -0.25. Sensei Biotherapeutics has a 1 year low of $6.32 and a 1 year high of $36.76.

Trending Headlines about Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: HC Wainwright initiated/expanded coverage on Sensei Biotherapeutics with a Buy rating and $60 price target, implying substantial upside from current levels. Benzinga
• Neutral Sentiment: The firm released detailed earnings estimates for 2026 through 2030, forecasting ongoing losses in the near term and later-period EPS projections that may help shape investor expectations. Benzinga

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.